Comparative analysis of alternative and traditional immunohistochemical markers for the distinction of ovarian sertoli cell tumor from endometrioid tumors and carcinoid tumor: A study of 160 cases

American Journal of Surgical Pathology

Volumn 31, Issue 2, 2007, Pages 255-266

  Zhao, Chengquan ^a,c,e   Bratthauer, Gary L ^a   Barner, Ross ^a,d   Vang, Russell ^b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Carcinoid tumor; Endometrioid carcinoma; Immunohistochemistry; Ovary; Sertoli cell tumor

Indexed keywords

CALRETININ; CD56 ANTIGEN; CD99 ANTIGEN; CHROMOGRANIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 7; CYTOKERATIN 8; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; INHIBIN; PROGESTERONE RECEPTOR; SYNAPTOPHYSIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CARCINOID; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY; OVARY CELL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SERTOLI CELL TUMOR; STATISTICAL SIGNIFICANCE; TUMOR DIAGNOSIS;

CARCINOID TUMOR; CARCINOMA, ENDOMETRIOID; CELL COUNT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; NEUROSECRETORY SYSTEMS; OVARIAN NEOPLASMS; SERTOLI CELL TUMOR; TUMOR MARKERS, BIOLOGICAL;

EID: 33846594846     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000213355.72638.f4     Document Type: Article

References (55)

1. Al-Khafaji B, Noffsinger AE, Miller MA, et al. Immunohistologic analysis of gastrointestinal and pulmonary carcinoid tumors. Hum Pathol. 1998;29:992-999.
2. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003;442:271-277.
3. Augusto D, Leteurtre E, De La Taille A, et al. Calretinin: a valuable marker of normal and neoplastic Leydig cells of the testis. Appl Immunohistochem Mol Morphol. 2002;10:159-162.
4. Baker PM, Oliva E, Young RH, et al. Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases. Am J Surg Pathol. 2001;25:557-568.
5. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429.
6. Cao QJ, Jones JG, Li M. Expression of calretinin in human ovary, testis, and ovarian sex cord-stromal tumors. Int J Gynecol Pathol. 2001;20:346-352.
7. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol. 2005;36:195-201.
8. Choi YL, Kim HS, Ahn G. Immunoexpression of inhibin alpha subunit, inhibin/activin betaA subunit and CD99 in ovarian tumors. Arch Pathol Lab Med. 2000;124:563-569.
9. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
10. Ciris M, Erhan Y, Zekioglu O, et al. Inhibin alpha and beta expression in ovarian stromal tumors and their histological equivalences. Acta Obstet Gynecol Scand. 2004;83:491-496.
11. Costa MJ, Morris RJ, Wilson R, et al. Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. Hum Pathol. 1992;23:787-797.
12. Costa MJ, Ames PF, Walls J, et al. Inhibin immunohistochemistry applied to ovarian neoplasms: a novel, effective, diagnostic tool. Hum Pathol. 1997;28:1247-1254.
13. Deavers MT, Malpica A, Liu J, et al. Ovarian sex cord-stromal tumors: an immunohistochemical study including a comparison of calretinin and inhibin. Mod Pathol. 2003;16:584-590.
14. Dionigi A, Facco C, Tibiletti MG, et al. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol. 2000;114:111-122.
15. Doglioni C, Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
16. Flemming P, Grothe W, Maschek H, et al. The site of inhibin production in ovarian neoplasms. Histopathology. 1996;29:465-468.
17. Gordon MD, Corless C, Renshaw AA, et al. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol. 1998;11:769-773.
18. Groisman GM, Meir A, Sabo E. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int J Gynecol Pathol. 2004;23: 52-57.
19. Guerrieri C, Franlund B, Malmstrom H, et al. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int J Gynecol Pathol. 1998;17:266-271.
20. Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identification of granulosa cell tumors of the ovary. Hum Pathol. 1997;28:1387-1395.
21. Iczkowski KA, Bostwick DG, Roche PC, et al. Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol. 1998;11:774-779.
22. Kato N, Fukase M, Ono I, et al. Sertoli-stromal cell tumor of the ovary: immunohistochemical, ultrastructural, and genetic studies. Hum Pathol. 2001;32:796-802.
23. Khin EE, Kikkawa F, Ino K, et al. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma. Int J Gynecol Pathol. 2003;22:175-180.
24. Kimura N, Pilichowska M, Okamoto H, et al. Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. Mod Pathol. 2000;13:140-146.
25. Kommoss F, Oliva E, Bhan AK, et al. Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study. Mod Pathol. 1998;11:656-664.
26. Kommoss F, Oliva E, Bittinger F, et al. Inhibin-α CD99, HEA125, PLAP, and chromogranin immunoreactivity in testicular neoplasms and the androgen insensitivity syndrome. Hum Pathol. 2000;31: 1055-1061.
27. Lantuejoul S, Moro D, Michalides RJ, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol. 1998;22:1267-1276.
28. Loo KT, Leung AK, Chan JK. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Histopathology. 1995;27:388-390.
29. Lugli A, Forster Y, Haas P, et al. Calretinin expression in human normal and neoplastic tissues: a tissue microarray analysis on 5233 tissue samples. Hum Pathol. 2003;34:994-1000.
30. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29:840-845.
31. McCluggage WG, Maxwell P. Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. Histopathology. 1999;35:216-220.
32. McCluggage WG, Maxwell P. Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001;38:403-408.
33. McCluggage WG, Maxwell P, Sloan JM. Immunohistochemical staining of ovarian granulosa cell tumors with monoclonal antibody against inhibin. Hum Pathol. 1997;28:1034-1038.
34. McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathology. 2003;43:144-150.
35. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26:1477-1483.
36. Oliva E, Vu Q, Young RH. CD10 expression in sex cord-stromal tumors (SCSTs) and steroid cell tumors (StCTs) of the ovary. [Abstract]. Mod Pathol. 2002;15:204A.
37. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29:143-156.
38. Ordi J, Schammel DP, Rasekh L, et al. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol. 1999;12:933-940.
39. Ordi J, Nogales FF, Palacin A, et al. Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am J Surg Pathol. 2001;25:1540-1545.
40. Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol. 2003;27:178-186.
41. Pelkey TJ, Frierson HF Jr, Mills SE, et al. The diagnostic utility of inhibin staining in ovarian neoplasms. Int J Gynecol Pathol. 1998; 17:97-105.
42. Ramalingam P, Malpica A, Silva EG, et al. The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. Am J Surg Pathol. 2004;28:1499-1505.
43. Riopel MA, Perlman EJ, Seidman JD, et al. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas. Int J Gynecol Pathol. 1998; 17:46-53.
44. Rishi M, Howard LN, Bratthauer GL, et al. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 1997;21:583-589.
45. Sidhu J, Sanchez RL. Prostatic acid phosphatase in strumal carcinoids of the ovary. An immunohistochemical study. Cancer. 1993;72:1673-1678.
46. Stagno PA, Petras RE, Hart WR. Strumal carcinoids of the ovary. An immunohistologic and ultrastructural study. Arch Pathol Lab Med. 1987;111:440-446.
47. Stewart CJ, Jeffers MD, Kennedy A. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumours and their histological mimics. Histopathology. 1997;31:67-74.
48. Van Eeden S, Quaedvlieg PF, Taal BG, et al. Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol. 2002;33:1126-1132.
49. Vang R, Herrmann ME, Tavassoli FA. Comparative immunohistochemical analysis of granulosa and sertoli components in ovarian sex cord-stromal tumors with mixed differentiation: potential implications for derivation of sertoli differentiation in ovarian tumors. Int J Gynecol Pathol. 2004;23:151-161.
50. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
51. Yao DX, Soslow RA, Hedvat CV, et al. Melan-A (A103) and inhibin expression in ovarian neoplasms. Appl Immunohistochem Mol Morphol. 2003;11:244-249.
52. Zamecnik M. Correspondence re: Mikami Y, Hata S, Kiyokawa T, Manabe T. Expression of CD10 in malignant mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod pathol. 2002;15:923-930 [Letter].
53. Mod Pathol. 2003;16: 618-619.
54. Zheng W, Sung CJ, Hanna I, et al. Alpha and beta subunits of inhibin/activin as sex cord-stromal differentiation markers. Int J Gynecol Pathol. 1997;16:263-271.
55. Zheng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 1998;69:23-31.